Redeye returns with an updated view following Elicera’s Q1 report and encouraging data from the phase I/II CARMA study, evaluating ELC-301 in diffuse large B-cell lymphoma (DLBCL). Based on the positive clinical signals, we have raised our assumptions related to the likelihood of approval and potential deal terms for ELC-301. In addition, we have lowered the WACC in accordance with Redeye’s revised rating model. These changes result in a higher valuation range.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/